326 related articles for article (PubMed ID: 22689681)
41. RUNX1 mutation and elevated FLT3 gene expression cooperates to induce inferior prognosis in cytogenetically normal acute myeloid leukemia patients.
Rehman A; Akram AM; Chaudhary A; Sheikh N; Hussain Z; Alsanie WF; Rehman RA; Hameed N; Saleem T; Zafar A; Absar M; Iqbal Z; Alhazmi A; Baeshen HA; Mohammedsaleh ZM; Qamer S; Sayed S; Gaber A
Saudi J Biol Sci; 2021 Sep; 28(9):4845-4851. PubMed ID: 34466057
[TBL] [Abstract][Full Text] [Related]
42. Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.
Metzeler KH; Bloomfield CD
Adv Exp Med Biol; 2017; 962():175-199. PubMed ID: 28299658
[TBL] [Abstract][Full Text] [Related]
43. Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt-related transcription factor 1 mutation: A single-center retrospective analysis.
Wang LY; Li Y; Jiang Q; Jiang H; Wang Y; Xu LP; Zhang XH; Liu KY; Tang FF
Hematol Oncol; 2024 Mar; 42(2):e3256. PubMed ID: 38367260
[TBL] [Abstract][Full Text] [Related]
44. Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML.
Stengel A; Kern W; Meggendorfer M; Nadarajah N; Perglerovà K; Haferlach T; Haferlach C
Leukemia; 2018 Feb; 32(2):295-302. PubMed ID: 28751771
[TBL] [Abstract][Full Text] [Related]
45. Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.
Kühnl A; Valk PJ; Sanders MA; Ivey A; Hills RK; Mills KI; Gale RE; Kaiser MF; Dillon R; Joannides M; Gilkes A; Haferlach T; Schnittger S; Duprez E; Linch DC; Delwel R; Löwenberg B; Baldus CD; Solomon E; Burnett AK; Grimwade D
Blood; 2015 May; 125(19):2985-94. PubMed ID: 25805812
[TBL] [Abstract][Full Text] [Related]
46. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.
Hollink IH; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Zimmermann M; Peeters JK; Valk PJ; Balgobind BV; Sonneveld E; Kaspers GJ; de Bont ES; Trka J; Baruchel A; Creutzig U; Pieters R; Reinhardt D; Zwaan CM
Haematologica; 2011 Mar; 96(3):384-92. PubMed ID: 21134981
[TBL] [Abstract][Full Text] [Related]
47. Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia.
Grossmann V; Kern W; Harbich S; Alpermann T; Jeromin S; Schnittger S; Haferlach C; Haferlach T; Kohlmann A
Haematologica; 2011 Dec; 96(12):1874-7. PubMed ID: 21828118
[TBL] [Abstract][Full Text] [Related]
48. Gene mutation profile and risk stratification in AML1‑ETO‑positive acute myeloid leukemia based on next‑generation sequencing.
Yu G; Yin C; Wu F; Jiang L; Zheng Z; Xu D; Zhou J; Jiang X; Liu Q; Meng F
Oncol Rep; 2019 Dec; 42(6):2333-2344. PubMed ID: 31638252
[TBL] [Abstract][Full Text] [Related]
49. Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
Duployez N; Marceau-Renaut A; Boissel N; Petit A; Bucci M; Geffroy S; Lapillonne H; Renneville A; Ragu C; Figeac M; Celli-Lebras K; Lacombe C; Micol JB; Abdel-Wahab O; Cornillet P; Ifrah N; Dombret H; Leverger G; Jourdan E; Preudhomme C
Blood; 2016 May; 127(20):2451-9. PubMed ID: 26980726
[TBL] [Abstract][Full Text] [Related]
50. Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.
Tsai SC; Shih LY; Liang ST; Huang YJ; Kuo MC; Huang CF; Shih YS; Lin TH; Chiu MC; Liang DC
Clin Cancer Res; 2015 Aug; 21(15):3541-51. PubMed ID: 25840971
[TBL] [Abstract][Full Text] [Related]
51. Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older.
Prassek VV; Rothenberg-Thurley M; Sauerland MC; Herold T; Janke H; Ksienzyk B; Konstandin NP; Goerlich D; Krug U; Faldum A; Berdel WE; Wörmann B; Braess J; Schneider S; Subklewe M; Bohlander SK; Hiddemann W; Spiekermann K; Metzeler KH
Haematologica; 2018 Nov; 103(11):1853-1861. PubMed ID: 29903761
[TBL] [Abstract][Full Text] [Related]
52. [Analysis of RUNX1 Gene Mutation in Patients with Myelodysplastic Syndrome].
Cai XH; Chen MY; Chao HY; Jiang NK; Lu XZ; Han WM; Qin W; Jia ZX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):202-208. PubMed ID: 32027277
[TBL] [Abstract][Full Text] [Related]
53. In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline.
Mendler JH; Maharry K; Becker H; Eisfeld AK; Senter L; Mrózek K; Kohlschmidt J; Metzeler KH; Schwind S; Whitman SP; Khalife J; Caligiuri MA; Klisovic RB; Moore JO; Carter TH; Marcucci G; Bloomfield CD
Haematologica; 2013 Aug; 98(8):e92-4. PubMed ID: 23753029
[No Abstract] [Full Text] [Related]
54. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.
Shi JL; Fu L; Wang WD
Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662
[TBL] [Abstract][Full Text] [Related]
55. Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells.
Goyama S; Schibler J; Cunningham L; Zhang Y; Rao Y; Nishimoto N; Nakagawa M; Olsson A; Wunderlich M; Link KA; Mizukawa B; Grimes HL; Kurokawa M; Liu PP; Huang G; Mulloy JC
J Clin Invest; 2013 Sep; 123(9):3876-88. PubMed ID: 23979164
[TBL] [Abstract][Full Text] [Related]
56. AML1/RUNX1 gene point mutations in childhood myeloid malignancies.
Migas A; Savva N; Mishkova O; Aleinikova OV
Pediatr Blood Cancer; 2011 Oct; 57(4):583-7. PubMed ID: 21294243
[TBL] [Abstract][Full Text] [Related]
57. Distinct gene expression pattern of RUNX1 mutations coordinated by target repression and promoter hypermethylation in acute myeloid leukemia.
Li J; Jin W; Tan Y; Wang B; Wang X; Zhao M; Wang K
Front Med; 2022 Aug; 16(4):627-636. PubMed ID: 34958450
[TBL] [Abstract][Full Text] [Related]
58. Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia.
Hou HA; Liu CY; Kuo YY; Chou WC; Tsai CH; Lin CC; Lin LI; Tseng MH; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Huang SY; Ko BS; Hsu SC; Chen CY; Lin CT; Wu SJ; Tsay W; Tien HF
Oncotarget; 2016 Feb; 7(8):9084-101. PubMed ID: 26812887
[TBL] [Abstract][Full Text] [Related]
59. Investigations of the prognostic value of RUNX1 mutation in acute myeloid leukemia patients: Data from a real-world study.
Wan CL; Huang YH; Huang SM; Xu YL; Tan KW; Yan-Qiu ; Shen XD; Ge SS; Cao HY; Li YY; Liu SB; Qi JJ; Dai HP; Xue SL
Leuk Res; 2024 Apr; 139():107483. PubMed ID: 38493755
[TBL] [Abstract][Full Text] [Related]
60. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]